Research article

**Frequency of tuberculous and non-tuberculous mycobacteria in HIV infected patients from Bogota, Colombia**

Martha I Murcia-Aranguren¹, Jorge E Gómez-Marin*²,³, Fernando S Alvarado³, José G Bustillo⁴, Ellen de Mendivelson⁴, Bertha Gómez⁵, Clara I León⁶, William A Triana⁷, Erwing A Vargas⁷ and Edgar Rodríguez⁷

Address: ¹Departamento de Microbiología, Facultad de Medicina-Universidad Nacional de Colombia, Bogota, Colombia, ²Centro de Investigaciones Biomédicas, Facultad de Ciencias de la Salud, Programa de Medicina, Universidad del Quindío, Armenia, Colombia, ³Unidad de Infectología, Departamento de Medicina Interna, Facultad de Medicina-Universidad Nacional de Colombia, Bogota, Colombia, ⁴Departamento de Medicina Interna, Hospital Simón Bolívar, Bogota, ⁵Programa VIH/SIDA, Instituto de Seguros Sociales, CAB Chapinero, Bogota, Colombia, ⁶Grupo de Micobacterias, Instituto Nacional de Salud, Bogota, Colombia and ⁷Estudiantes de Medicina, Facultad de Medicina, Universidad Nacional de Colombia, Bogota, Colombia Armenia, Colombia

E-mail: Martha I Murcia-Aranguren - mimurcia@usa.net; Jorge E Gómez-Marin* - jegomezmarin@hotmail.com; Fernando S Alvarado - falvarado@cfl.rr.com; José G Bustillo - jbastian@hotmail.com; Ellen de Mendivelson - hospitalsimonbolivar@yahoo.com; Bertha Gómez - berthaiss@latinmail.com; Clara I León - cleon@hemagogus.ins.gov.co; William A Triana - watrianr@hotmail.com; Erwing A Vargas - vsa79@latinmail.com; Edgar Rodríguez - e_rodriguez_beltran@altavista.com

*Corresponding author

**Abstract**

**Background:** The prevalence of infections by *Mycobacterium tuberculosis* and non-tuberculous *Mycobacterium* species in the HIV-infected patient population in Colombia was uncertain despite some pilot studies. We determined the frequency of isolation of *Mycobacterium tuberculosis* and of non-tuberculous *Mycobacterium* species in diverse body fluids of HIV-infected patients in Bogota, Colombia.

**Methods:** Patients who attended the three major HIV/AIDS healthcare centres in Bogota were prospectively studied over a six month period. A total of 286 patients were enrolled, 20% of them were hospitalized at some point during the study. Sixty four percent (64%) were classified as stage C, 25% as stage B, and 11% as stage A (CDC staging system, 1993). A total of 1,622 clinical samples (mostly paired samples of blood, sputum, stool, and urine) were processed for acid-fast bacilli (AFB) stain and culture.

**Results:** Overall 43 of 1,622 cultures (2.6%) were positive for mycobacteria. Twenty-two sputum samples were positive. Four patients were diagnosed with *M. tuberculosis* (1.4%). All isolates of *M. tuberculosis* were sensitive to common anti-tuberculous drugs. *M. avium* was isolated in thirteen patients (4.5%), but only in three of them the cultures originated from blood. The other isolates were obtained from stool, urine or sputum samples. In three cases, direct AFB smears of blood were positive. Two patients presented simultaneously with *M. tuberculosis* and *M. avium*.

**Conclusions:** Non-tuberculous *Mycobacterium* infections are frequent in HIV infected patients in Bogota. The diagnostic sensitivity for infection with tuberculous and non-tuberculous mycobacteria can be increased when diverse body fluids are processed from each patient.

**Published:** 8 November 2001

**BMC Infectious Diseases 2001, 1:21**

**Received:** 25 July 2001

**Accepted:** 8 November 2001

© 2001 Murcia-Aranguren et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-commercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact info@biomedcentral.com
Background

*Mycobacterium* infections are frequent opportunistic pathogens associated with the acquired immunodeficiency syndrome (AIDS). Its relative virulence and potential for person-to-person transmission distinguishes *Mycobacterium tuberculosis*. Persons infected with the human immunodeficiency virus (HIV) are particularly susceptible to tuberculosis, either by the reactivation of latent infection or by a primary infection with rapid progression to active disease [1–4]. The annual incidence rate of tuberculosis in Colombia during 1998 was 19.6 per 100,000 persons [5], but rates 1,000-fold higher have been reported in some HIV-seropositive populations [6–14]. In addition, disseminated infections with *Mycobacterium avium* complex are increasingly common in advanced human immunodeficiency virus (HIV) disease and cause substantial morbidity [15,16]. Persons with HIV infection and CD4 lymphocyte counts less than 100 cells/mm³ have a probability of 10% to 20% per year of developing *M. avium* complex disease or bacteremia [17,18]. Bacteremia involving *M. avium* complex produces a wide array of clinical signs and symptoms, including wasting, fever, and night sweats, and is associated with decreased survival [17–20]. The recovery of mycobacteria in blood cultures can help to discover bacteremia that frequently goes unrecognized. We undertook a prospective survey in three AIDS health care units in Bogota, Colombia, in order to determine the prevalence of *Mycobacterium* species in HIV-infected patients and to evaluate the diagnostic value of different types of body fluids to detect the presence of mycobacteria.

Methods

Patients and study design

This study was a multicentric prospective study of the frequency of *Mycobacterium* infections in persons infected with HIV. The study was conducted in three major AIDS health care programs of Bogota ("Hospital Universitario San Juan de Dios", "Hospital Regional Simon Bolívar" and "Centro Atención Básica Chapinero del Seguro Social"). From October 1999 to March 2000, a total of 289 HIV-seropositive patients were recruited. Most of the participants met the definition of AIDS, or were in clinical stage C (CDC, 1993). The institutional review board at each site approved the study, and each participant gave written informed consent.

Specimen collection and culture media

For all patients blood, urine, stool and sputum samples were collected. In brief, 5 to 8 mL of blood was obtained in previously labeled Vacutainer™ tubes containing 1.7 mL of heparin as anticoagulant. All patients attempts were made to collect two paired blood cultures samples (n = 648), 2 urine cultures (n = 497), 2 stool cultures (n = 374) and 2 sputum samples (n = 101). In one patient a sample of ascitic fluid, and in other case cerebrospinal fluid (CSF) were obtained. Bacteriologic methods were used as previously described [21,22]. Briefly, blood samples were centrifuged 15 min at 2,000 g and leukocytes recovered by standard methods with Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) and then mixed with a lysing solution that contained 0.45% sodium deoxycholate. After manual mixing, tubes were centrifuged at 3,500 g for 30 minutes in a refrigerated centrifuge at 4,000 g and the supernatant was discarded. The pellet was resuspended, and 0.2% bovine albumin was added to yield a final volume of 2.5 mL.

One gr of stool samples was placed in 5 ml of albumin Dubos media and mixed in Vortex™ for 2 min, then incubated at room temperature overnight. Afterwards, equal volumes of a solution of 2% NaOH were mixed in Vortex™ for 2 min and then incubated at room temperature in continuous mixing for 15 min. Distilled water was added to complete 50 ml and the mixture was centrifuged at 6,000 g for 30 min. One drop of phenol red was added to the pellet and then neutralized with 2 drops of HCl 2 N. The pellet was resuspended in 2 ml of saline solution, mixed and finally 0.2 ml used for culture.

Urine samples were mixed in a ratio of 3:1 with a solution of 20% Na₃PO₄·12H₂O. The mixture was incubated at room temperature for 2 h and then centrifuged at 6,000 g for 30 min. The pellet was used for culture after being decontaminated by Ogawa-Kudoh method. Briefly, sterile slabs were placed in a solution of 4% NaOH during 1 or 2 min and then used to culture samples.

Sputum was mixed in equal volume with a solution of 4% Na₃PO₄·12H₂O, incubated at room temperature during 2 h and centrifuged at 6,000 g for 30 min. The pellet was decontaminated by the Ogawa-Kudoh method, as described above, and used for culture. The same procedure was used for the ascitic fluid and CSF samples.

All samples were placed in 2 tubes with a biphasic medium: a solid phase Ogawa-Kudoh with iron citrate and a liquid phase of Sauton Twen albumin modified medium and 2 tubes with Stonebrink-Giraldo medium. Readings were made after day 6 and at 2, 4, 6, 8, 12 and 16 week. A positive culture was identified following the criteria of the Centers for Prevention and Disease Control (CDC) [22]. Resistance assay was applied at all *Mycobacterium tuberculosis* isolates using the proportion method for streptomycin (S), isoniazide (H), thioacetazone (Tb), ethambutol (E) and rifampicin (R).

All samples were stained and examined for AFB after centrifugation.
Statistical analysis
Statistical significance for comparison of rates was determined by an exact test when sample sizes were insufficient and by an asymptotic test when sizes were sufficient. All tests were two-sided, and a P value of 0.05 was considered significant. Exact 95% confidence intervals (CI) were calculated for rates by assuming the numerator to be a Poisson variable [23] and for rate ratios using a modified binomial model [24]. Adjusted rate ratios for comparisons among groups defined by demographic variables were calculated by using a Mantel-Haenszel type estimator for incidence-rate data with approximate 95% confidence limits based on the tests [23].

Results
Demographic characteristics
In total, 286 patients were studied, 251 (87.8 %) were men, and 35 (12.2%) were women. The men:women ratio was 7:1. The age range was 3 to 78 years with a median of 35 years (Table 1). Ten patients (3%) were from "Hospital San Juan de Dios"; one-hundred thirty nine patients (49%) were from "Hospital Simón Bolívar" and one hundred thirty seven patients (48%) were from the "Instituto de Seguro Social". Fifty-eight patients were hospitalized at the time of enrollment (20%), and two hundred twenty eight patients (80%) were enrolled at an outpatient clinic. One hundred ninety five patients (68.5%) were in treatment with antiretroviral medication. Sexual preferences were informed in 269 (94%) patients as follows: in males, ninety (33.4%) were homosexual, eighty-six (31.9%) were bisexual and sixty-one (22.7%) were heterosexual. Of the women, twenty-nine (90.6%) were heterosexual and three (9.4%) were bisexual. CDC staging in these patients is shown in Table 1. Viral load was obtained in 180 patients and results varied in a range between less than 50 and 13 millions copies/mL. The median of viral load was 23,420 copies/mL.

The symptoms most frequently complaint of at the time of initial enrollment were headaches (48%), loss of weight (43%), and mental status changes (38%). The frequency of each symptom is showed in Figure 1. 29% patients complaint of respiratory symptoms. 13% patients had a history of diagnosis of tuberculosis, and 12% gave a history of previous treatment with antituberculous drugs.

Table 1: Demographic characteristics of patients

| Distribution by center                  | n | %  |
|-----------------------------------------|---|----|
| Hospital San Juan de Dios               | 10|    |
| Male                                    | 9 | 90 |
| Women                                   | 1 | 10 |
| Hospital Simon Bolivar                  | 139|   |
| Male                                    | 128| 95 |
| Women                                   | 21 | 15 |
| Seguro Social                           | 137|   |
| Male                                    | 124| 90 |
| Women                                   | 13 | 10 |
| Age groups                              |   |    |
| 0 – 15                                   | 1 | 0.35 |
| 16 – 25                                  | 38| 13.3|
| 26 – 45                                  | 211| 73.8|
| 46 – 65                                  | 35| 12.2|
| 66 – 78                                  | 1 | 0.35 |
| 1993 CDC stages                         |   |    |
| A                                       | 31| 11 |
| B                                       | 69| 24 |
| C                                       | 186| 65 |

Mycobacterium infection
Overall, sixteen of 286 patients (5.6%) were positive for any Mycobacterium species by acid fast staining or culture of any of their samples. In these sixteen cases, fifteen (94%) were positive by culture, and one patient was detected only by acid fast bacilli staining (6%). Fourteen patients (87.5%) were men and two (12.5%) were women. M. tuberculosis was identified in four cases (1.4%). M. avium was isolated in thirteen patients (4.2%). Two patients presented simultaneous infection by M. tuberculosis and M. avium.

Tuberculosis was diagnosed in its pulmonary form in two cases, and in another two patients as extrapulmonary. In the patients with pulmonary tuberculosis, the AFB smear of the sputum was positive in one case, and in another
case the AFB smear was positive in his stool sample. Culture of stool samples was positive in both cases of pulmonary and in one case of extrapulmonary tuberculosis. *M. tuberculosis* was detected in different samples of body fluids as well: in sputum, urine, stool samples, and in ascitic fluid (Table 2). All isolates of *M. tuberculosis* were sensitive to the drugs assayed: streptomycin (S), isoniazide (H), thioacetazone (Th), ethambutol (E) and rifampicin (R).

The only species identified as non-tuberculous mycobacteria was *M. avium* which was detected in 13 patients (4.2%). Two patients had coinfection by *M. tuberculosis* and *M. avium* in their sputum culture. One patient was positive only for acid fast bacilli staining in two stool samples but no growth was observed in culture tubes after 16 weeks of incubation. Interestingly, in three patients the direct AFB staining in blood was positive, and *M. avium* was later identified in these blood cultures (Table 3). *M. avium* was also detected in other clinical samples: urine, stool and sputum (Table 4).

The percent of positive AFB smears and cultures was greater in samples of sputum followed by the samples of stool (Table 5). Samples of urine and stool were valuable to identify most of patients with a *M. avium* infection, only three patients infected by *M. avium* were identified solely by blood cultures (Table 6 and 7).

### Table 2: Staining and culture of *M. tuberculosis*

| Patient | Clinical form | Type of Sample | Number of Samples | AFB SMEAR POSITIVE | CULTURE POSITIVE |
|---------|---------------|----------------|-------------------|--------------------|------------------|
| 1       | Disseminated  | Sputum         | 2                 | 2                  | 2                |
|         |               | Urine          | 2                 | 0                  | 2                |
|         |               | Ascitic fluid  | 1                 | 1                  | 1                |
| 2       | Pulmonary     | Sputum         | 2                 | 2                  | 2                |
|         |               | Stool          | 2                 | 2                  | 2                |
| 3       | Pulmonary     | Sputum         | 2                 | 0                  | 2                |
|         |               | Stool          | 2                 | 1                  | 2                |
| 4       | Gastrointestinal | Stool     | 2                 | 2                  | 2                |
| TOTAL   |                |                | 15                | 10                 | 15               |

2* This patient also presented positive culture for *M. avium*

### Table 3: Staining and culture of *M. avium* in blood samples

| Patient | Sample | Number of Samples | AFB smear Positive | Negative | Culture Positive | Negative |
|---------|--------|-------------------|--------------------|----------|------------------|----------|
| 1       | blood  | 2                 | 1                  | 1        | 2                | 0        |
| 2       | blood  | 2                 | 1                  | 1        | 2                | 0        |
| 3       | blood  | 2                 | 1                  | 1        | 2                | 0        |
| 3*      | urine  | 2                 | 0                  | 2        | 2                | 0        |
|         | stool  | 2                 | 2                  | 0        | 2                | 0        |
| TOTAL   |        | 12                | 6                  | 6        | 12               | 0        |

3* Sample after one month of follow. This patient had past history of tuberculosis

### Association between Mycobacterium avium infection and clinical data

The following factors (Table 6) were significantly associated with a culture positive for *M. avium* infections: death during time of follow up (odds ratio [OR], 9.7 [95% CI, 2.8–32]), loss of weight (OR, 8 [95% CI, 1.6–54]), and diarrhea (OR, 3.9 [95% CI, 1.1–14]). The mean time of survival during the study was significantly reduced in patients infected with *Mycobacterium avium* compared to the ones not infected (154 ± 44 versus 170 ± 37 days, *p* = 0.01). There were no statistically significant differences in age, sex, clinical stage, CD4 cell count, viral load, use of antiretrovirals drugs or time of diagnosis since HIV infection between patients with or without myco-
bacterial infection (Table 7). However, there were no patients with M. avium infections in clinical stage A or with a CD4 cell count higher than 500 cells/mm$^3$ (Tables 8 and 9).

Table 4: Staining and culture of M. avium in clinical samples other than blood

| PATIENT | SAMPLE   | Number of Samples | AFB Smear | Culture |
|---------|----------|-------------------|----------|---------|
|         |          | POS | NEG | POS | NEG |
| 1       | Stool    | 2   | 0   | 2   | 1   |
| 2       | Stool    | 2   | 0   | 2   | 1   |
| 3       | Stool    | 2   | 2   | 0   | 2   |
| 4       | Urine    | 2   | 0   | 2   | 2   |
| 5       | Urine    | 2   | 0   | 2   | 2   |
| 6       | Urine    | 2   | 0   | 2   | 1   |
| 7       | Urine    | 2   | 0   | 2   | 0   |
| 8*      | Sputum   | 2   | 2   | 0   | 2   |
| 9*      | Sputum   | 2   | 2   | 0   | 1   |
| TOTAL   |          | 18  | 6   | 12  | 14  |

8* Patient with past history of TB 9* Patient with simultaneous finding of M. tuberculosis

Table 5: Positivity for Mycobacterium infection and type of sample (n = 1622)

| SAMPLE       | CULTURE | AFB Smear |
|--------------|---------|-----------|
|              | POSITIVE | NEGATIVE | POSITIVE | NEGATIVE |
|              | N | % | n | % | n | % |
| Blood        | 8 | 1.2 | 640 | 98.8 | 3 | 0.5 | 645 | 99.5 |
| Stool        | 12 | 3.2 | 362 | 96.8 | 11 | 3 | 363 | 97 |
| Sputum       | 3 | 0.8 | 93 | 92 | 6 | 6 | 93 | 94 |
| CSF          | 0 | 0 | 100 | 0 | 0 | 0 | 100 |
| Ascitic fluid| 1 | 100 | 0 | 0 | 1 | 100 | 0 | 0 |
| TOTAL        | 40 | 2.5 | 1582 | 97.5 | 22 | 1.3 | 1600 | 98.7 |

Table 6: Clinical findings associated with Mycobacterium avium infection

| Clinical findings | Odds Risk | CI 95% | p   |
|-------------------|-----------|--------|-----|
| Death*            | 9.7       | (2.8 – 32) | 0.0005 |
| Loss of weight*   | 8.0       | (1.6 – 54) | 0.004 |
| Diarrhea*         | 4.5       | (1.1 – 14) | 0.017 |
| Hemoptysis        | 3.6       | (0.1 – 16) | 0.1 |
| Cough             | 2.1       | (0.6 – 6.9) | 0.2 |
| Hospitalization   | 2.5       | (0.7 – 8.3) | 0.1 |
| History of past TB| 2.1       | (0.4 – 7.9) | 0.2 |
| Dyspnea           | 1.9       | (0.5 – 6.8) | 0.2 |
| Fever             | 1.7       | (0.5 – 5.5) | 0.3 |
| Lymphadenopaties  | 1.0       | (0.2 – 5.7) | 1.0 |

* Statistically significant associations p < 0.05

Discussion

Our study was a prospective study in HIV infected patients in whom an indiscriminate search Mycobacterium infection was done. Clinical suspicion of tuberculosis existed previous to enrollment only in the two patients with pulmonary Mycobacterium tuberculosis infection but not in the other two patients with extrapulmonary tuberculosis.

Most of Mycobacterium species isolated were M. avium

The frequency that we found was lower than that of previously reported studies for Mycobacterium in HIV in-
fected patients in Colombia. A previous study at the "Hospital San Juan de Dios" in 1996 performed in 92 HIV infected patients found a prevalence of 8% for M. tuberculosis infection [25]. In another study in 101 patients in Cali, Colombia, the prevalence was only 2% [26]. In the present study it was 1.4%.

The prevalence of non-tuberculous Mycobacterium species in Cali was 5% [27], and in the current study it was 4%. The lower prevalence of M. tuberculosis, can be related to the introduction of highly active antiretroviral therapy (HAART) that was practically absent in the previous study in Bogota in 1996 but that was being used to treat 68% of the patients in the current study. Our results are also different to the ones reported in a General Hospital, AIDS reference center, in Rio de Janeiro, Brazil [28] where mycobacteria were recovered from 20.6% (313 of 1,517) of all patients, and M. tuberculosis was identified in 94.2% (295/313), and non-tuberculous mycobacteria in 5.8% (18/313). Our results suggest that when antiretroviral therapy is introduced the relative frequency of M. tuberculosis infections is reduced and the one of M. avium infections increases [28].

We found that Mycobacterium avium infection was related to symptomatic diarrhea and greater mortality as has been reported previously [29]. Our study shows that frequency of isolation of M. avium was greater in urine and stool samples. This emphasizes the need to take multiple body fluid samples in order to enhance the opportunity of isolation increasing the microbiologic diagnostic sensitivity. Interestingly, we found that blood AFB smears can be useful to rapidly confirm a clinical diagnosis of disseminated Mycobacterium avium infection.

In the present study there were no resistant strains of M. tuberculosis found. In a previous survey in Colombia it was found that M. tuberculosis isolates among new cases in patients without HIV infection showed resistance in 9.5% (4 of 42) [30].

### Table 7: Demographic and clinical characteristics in patients with and without Mycobacterium avium infection

|                        | Patients with M. avium infection | 1st and 3rd quartile | Patients without M. avium infection | 1st and 3rd quartile | p  |
|------------------------|---------------------------------|----------------------|-------------------------------------|----------------------|----|
|                        | N (patients with data) | Median or percent | N (patients with data) | Median or percent |    |
| Age                    | 13                              | 33 [23–39]          | 273                                | 35 [29–40]          | 0.2|
| Sex male               | 13                              | 92%                 | 273                                | 88%                 | 0.5|
| CD4 cell counts        | 13                              | 115 [30–223]        | 219                                | 164 [60–325]        | 0.2|
| Viral load             | 8                               | 52,000 [5,967–227,941] | 172                                | 23,000 [746–147,131] | 0.5|
| Use of antiretrovirals | 13                              | 61.5%               | 272                                | 68.7%               | 0.8|
| Time with antiretroviral treatment (months) | 10                              | 29 [18–60]          | 175                                | 22 [12–32]          | 0.2|
| Time with diagnosis of VIH infection (months) | 10                              | 18.5 [15–28]        | 175                                | 27 [13–50]          | 0.2|

### Table 8: Clinical stage of HIV infection and positivity for Mycobacterium infection

| CLINICAL STAGE | POSITIVE | TOTAL |
|----------------|----------|-------|
| A              | 0 (0%)   | 0/31 (0%) |
| B              | 3 (19%)  | 3/69 (4.4%) |
| C              | 13 (81%) | 13/186 (7%) |
| TOTAL          | 16 (100%)| 16/286 (5.6%) |

### Table 9: Relation between CD4 cell count and infection with Mycobacterium

| CD4+ cells | POSITIVES | TOTAL |
|------------|-----------|-------|
| (> 500/mm³) | 0 (0%)   | 0/24 (0%) |
| (200–499/mm³) | 6 (37%)  | 6/83 (7.2%) |
| (< 200/mm³) | 8 (50%)  | 8/126 (6.3%) |
| ND          | 2 (13%)  | 2/53 (3.7%) |
| TOTAL       | 16 (100%)| 16/262 (6.1%) |
Conclusions
Our study found that 5% of HIV infected patients in Bogota were infected with Mycobacteria and that M. Avium was the predominant species. It becomes evident the need to improve the preventive measures and prompt treatment of this type of opportunistic infection in the HIV infected individuals.

Competing interests
None declared

Acknowledgement
This work was financed by the Ministry of Health of Colombia, contract 809154, and by DIB (Universidad Nacional de Colombia), grant 701–98.

References
1. Center for Disease Control and Prevention: Transmisión of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988–1991. MMWR Morb Mortal Wkly Rep 1991, 40:129-131
2. Center for Disease Control and Prevention: Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Bogota, Colombia, 1990. MMWR Morb Mortal Wkly Rep 1991, 40:585-591
3. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, Hopewell PC: An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992, 326:231-235
4. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, KR Ong, Kilburn JO, Dooley SW, Castro KG, et al: An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992, 326:1514-1521
5. Victoria JE: Epidemiología de la tuberculosis en Colombia. Informe Quincenal Epidemiológico Nacional 1999, 4:82-85
6. Allen S, Batungwanayo J, Kerlikowske K, Lifson AR, Wolf WR, Granich R, Taemaen H, Van de Perre P, Serufilya A, Bogaerts J, et al: Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992, 146:1432-1444
7. Selwyn PA, Scelll BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE: High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992, 268:504-509
8. Guelar A, Gestal JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, Miro JM, Mallolas J, Zamora L, Gonzales J, et al: A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993, 7:1345-1349
9. Moreno S, Barcia-Exaburuz J, Bouza E, Parras F, Perez-Tascon M, Mirailes P, et al: Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993, 119:194-198
10. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD: Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993, 342:268-272
11. Melnick SL, Sherer R, Louis TA, Hillman D, Rodriguez EM, Lackman C, Capo L, Brown LS, Cabbin M, Korvick JA, et al: Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1994, 272:1915-1921
12. Graham NM, Cohn S, Galai N, Assemborg J, Nelson KE, Walhov D: Incidence of mycobacterial infection and disease in HIV+ and HIV- IDUs [Abstract]. Int Conf AIDS 1993, 9:328
13. Antonucci G, Girardi E, Raviglione MC, Ippolito G: Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tuberculosis e AIDS (GISTA), JAMA 1995, 274:143-148
14. Dupon M, Texier-Maugein M, Leroy V, Senthilves A, Perlegerin JL, Morlat P, et al: Tuberculosis and HIV infection: a cohort study of incidence and susceptibility to antituberculous drugs. Bourdeaux, 1985–1993. Groupe d’Epidemiologie Clinique du SIDA en Aquitaine. AIDS 1995, 9:577-583
15. Horsburgh CR: Mycobacterium avium-complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:1332-1338
16. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, et al: Clinical manifestations of AIDS in the era of Pneumocystis carinii prophylaxis. N Engl J Med 1993, 329:1922-1926
17. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T: Incidence and natural history of Mycobacterium avium complex infections in patients with advanced HIV disease treated with zidovudine. The Zidovudine Epidemiology Study Group, Am Rev Respir Dis 1992, 146:285-289
18. Nightengale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA: Incidence of Mycobacterium avium – intracellulare complex bacteriaemia in human immunodeficiency virus-positive patients. J Infect Dis 1992, 165:1082-1085
19. Horsburgh CR, Havlik JA, Ellis DA, Kennedy E, Fann SA, Dubois RE, Thompson SE: Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991, 144:557-559
20. Jacobson MA, Hopewell PC, Yakko DM, Hadley WY, Lazarus E, Mo-hany PK, GW Modin, Feigal DW, Cusick PS, Sande MA: Natural his- tory of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1991, 164:994-998
21. Instituto Nacional de Salud: Tuberculosis, Manual de Procedimientos. Bogota 1990
22. Center for Diseases Control: Mycobacteriology, A guide for the level III laboratory Atlanta 1985
23. Rothman KJ: Modern Epidemiology. Boston: Little, Brown 1986, 155, 172-196-213
24. Kahn HA, Sempós CT: Statistical Methods in Epidemiology New York: Oxford Univ Pr 1989
25. Murcia M, León CI, de la Hoz F, Saravia J: Frecuencia de las infecciones micobacterianas en pacientes VIH positivos que acuden a las consultas del Hospital San Juan de Dios. Biomedica 1996, 16(suppl 1):23
26. Crespo M, Corral R, Alzate A: El diagnostico de la infección por micobacterias en individuos VIH positivos. Colombia Medica 1994, 25:86-91
27. Cande MB, Figueira CM, Moraes R, Fonseca LS, Deriemer K, Kritski AL: Predictive value of the acid fast smear for detection of Mycobacterium tuberculosis in respiratory specimens in a reference center of HIV/AIDS in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz 1999, 94:787-790
28. Horsburgh CR: Epidemiology of mycobacterial diseases in AIDS. Res Microbical 1992, 143:372-377
29. Coker RJ, Hellyer TJ, Brown IN, Weber JN: Clinical aspects of mycobacterial infections in HIV infection. Res Microbiol 1992, 143:377-381
30. Gómez Marín JE, Rigouts L, Villegas Londoño LE, Portaels F: Restriction Fragment Length Polymorphism (RFLP) analysis and tuberculosis epidemiology. Boll PAHO 1995, 29:226-236